Management of non‐functional pancreatic neuroendocrine tumors by endoscopic ultrasound‐guided radiofrequency ablation: Retrospective study in two tertiary centers.

Autor: Marx, Mariola, Godat, Sébastien, Caillol, Fabrice, Poizat, Flora, Ratone, Jean‐Philippe, Pesenti, Christian, Schoepfer, Alain, Hoibian, Solène, Dahel, Yanis, Giovannini, Marc
Předmět:
Zdroj: Digestive Endoscopy; Sep2022, Vol. 34 Issue 6, p1207-1213, 7p
Abstrakt: Background: Recently, there has been growing interest in investigating endoscopic ultrasound‐guided radiofrequency ablation (EUS‐RFA) for the management of small non‐functional pancreatic neuroendocrine tumors (nf pNETs). Patients and Methods: A bicentric retrospective study was performed that included patients with histologically confirmed nf pNETs who were consecutively treated by EUS‐RFA between December 2015 and March 2021 at two tertiary referral centers. Results: In 27 patients (mean age 65.0 years, 52% male), EUS‐RFA was successfully performed. All patients had sporadic G1 lesions (mean size 14.0 ± 4.6 mm, 7% uncinated process, 22% head, 11% body, 19% body/tail junction, and 41% tail). Overall, 9/27 lesions (33%) were cystic. The mean hospital stay was 3.2 days. Complete treatment response was confirmed in 25/27 patients (93%) on cross‐sectional imaging (mean follow‐up 15.7 ± 12.2 months, range 2–41 months). Two patients had two EUS‐RFA sessions until complete necrosis was observed. Periprocedural acute pancreatitis occurred in 4/27 (14.8%), three of them were treated by endoscopic cystogastrostomy (11.1%). One patient underwent secondary surgery. The histopathology of the resected specimen revealed 3 mm of residual tumor tissue. Conclusion: EUS‐RFA seems to be a promising treatment strategy for the management of small nf pNETs with excellent efficacy. Further evidence focusing on long‐term survival, safety profile and recurrence is needed. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje